左卡尼汀联合普拉克索治疗血液透析患者不宁腿综合征的疗效研究  

Study on the efficacy of levocarnitine combined with pramipexole in the treatment of restless legs syndrome in hemodialysis patients

作　　者：蔡志根[1] 林长达 林威远[1] CAI Zhigen;LIN Changda;LIN Weiyuan(Department of Nephrology,the Second Affiliated Hospital of Fujian Medical University,Fujian,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属第二医院肾内科,福建泉州362000

出　　处：《中国医药科学》2022年第9期111-114,共4页China Medicine And Pharmacy

基　　金：福建中医药大学校管科研课题(XB2019086)。

摘　　要：目的探讨左卡尼汀联合普拉克索治疗血液透析患者不宁腿综合征的临床疗效。方法选取2019年7月至2020年7月福建医科大学附属第二医院收治的维持性血液透析且合并不宁腿综合征的患者56例,按照随机数字表法分组,对照组28例予以普拉克索片治疗,研究组28例予以普拉克索片+左卡尼汀治疗。比较两组治疗前后的IRLSSGRS、VAS评分、临床缓解率、PSQI评分以及不良反应发生率。结果治疗后,两组患者的IRLSSGRS、VAS评分均下降,差异有统计学意义(P<0.05)。治疗后,与对照组比较,研究组的IRLSSGRS、VAS评分下降更明显,差异有统计学意义(P<0.05)。研究组临床缓解率为82.14%,高于对照组的57.14%,差异有统计学意义(P<0.05)。治疗后,两组患者PSQI评分均降低,差异有统计学意义(P<0.05),与对照组比较,研究组治疗后PSQI评分降低更明显,差异有统计学意义(P<0.05)。研究组不良反应总发生率为17.86%,低于对照组的42.86%,差异有统计学意义(P<0.05)。结论左卡尼汀能明显提高普拉克索治疗血液透析患者不宁腿综合征的临床缓解率,改善睡眠质量,降低不良反应的发生率。Objective To investigate the clinical efficacy of levocarnitine combined with pramipexole in the treatment of restless legs syndrome in hemodialysis patients.Methods A total of 56 maintenance hemodialysis patients with restless legs syndrome admitted to the Second Affiliated Hospital of Fujian Medical University from July 2019 to July 2020 were selected as study subjects.They were grouped by random numbers,with 28 patients in the control group treated with pramipexole tablets and the other 28 patients in the study group treated with pramipexole tablets+levocarnitine.The International Restless Legs Syndrome Study Group rating scale(IRLSSGRS)score,Visual Analogue Scale(VAS)score,clinical remission rate,Pittsburgh Sleep Quality Index(PSQI)score and the incidence of advers e reactions(ARs)before and after treatm ent were compared between the two groups.Results After treatment,the IRLSSGRS scores and VAS scores in both groups were decreased,with statistically significant differences(P<0.05).After treatment,the IRLSSGRS scores and VAS scores decreased more significantly in the study group than in the control group,with statistically significant differences(P<0.05).The clinical remission rate in the study group(82.14%)was higher than that in the control group(57.14%),with statistically significant differences(P<0.05).After treatment,the PSQI scores in both groups were decreased,with statistically significant differences(P<0.05),and those in the study group decreased more significantly than those in the control group,with statistically significant differences(P<0.05).The total incidence of ARs in the study group(17.86%)was lower than that in the control group(42.86%),with statistically significant difference(P<0.05).Conclusion Levocarnitine can significantly improve the clinical r emission rate of res tless legs syndrome,improve sleep quality and reduce the incidence of ARs in hemodialysis patients treated with pramipexole.

关 键 词：不宁腿综合征 普拉克索 左卡尼汀 临床缓解率 睡眠质量 

分 类 号：R692.5[医药卫生—泌尿科学]